Acute cardiac care & resuscitation
Safety and Efficacy of up to 60 h of iv Istaroxime in Pre-Cardiogenic Shock Patients: Design of the SEISMiC Trial
Study context
- Population
- Patients hospitalised for decompensated HF (pre-CS, not related to myocardial ischaemia) with persistent hypotension (systolic blood pressure (SBP) 70–100 mmHg for ≥2 h), clinically confirmed congestion, NT-proBNP ≥1400 pg/mL and LVEF≤40%; no IV vasopressors, inotropes or digoxin in past 6 h
- Planned comparison
- IV istaroxime vs placebo for up to 60 h
- Primary endpoint
- SBP area under the curve from baseline, in combined Parts A and B population
- Follow-up
- 6 and 24 h
Methodological detailsdesign paper, multinational, multicentre, double-blind, placebo-controlled, two parts (A and B)
- Design paper
- Multinational
- Multicentre
- Double-blind
- Placebo-controlled
- Two parts (A and B)
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Safety and Efficacy of up to 60 h of iv Istaroxime in Pre-Cardiogenic Shock Patients: Design of the SEISMiC Trial. ESC Heart Fail. Published 7 October 2024. doi:10.
Summarised from the published abstract; every number is checked against it